1st P2 DCM patient but a $7+ M initial cost – still a SELL
The ixCELL-DCM study will initially and approximately cost about $7M to commence. If recruitment completes by early 2014, the data will presented in Q215. Again, ASTM has increased the number of sites participating in “this” study which will help in patient enrollment and complete the trial on schedule. However, funding of $30 -$35m until the end of 2015 will be needed. It also seems to have a “new” acting chief medical officer – David Recker, MD. ASTM closed at $0.79 -$0.01 with 332.5 K shares traded and is down $0.03 or -3.18% to $0.76 with 49 K shares trading – still a – STRONG SELL.